6 evidence-first reviews in this topic, built on 43 peer-reviewed citations. Null and negative trials are reported alongside the positive ones — that is the point of the format.
A semaglutide trial moved epigenetic clocks, but weight loss, organ protection, biomarkers and lifespan are four different claims.
Where the evidence lands: Semaglutide has strong disease-specific outcome evidence and an intriguing epigenetic signal, but no trial proves it reverses aging or extends lifespan in healthy people.
Protein can activate growth signaling and preserve muscle. Human evidence says the right question changes with age, food source, training, and kidney health.
Where the evidence lands: Protein is neither a universal longevity accelerator nor a toxin. Human data support adequate protein and resistance training for muscle preservation, especially later in life, while mortality cohorts more consistently favor plant sources than any single total-protein target.
Reactive oxygen species can damage cells, but they also carry essential signals. Large trials show why an antioxidant pill is not bottled longevity.
Where the evidence lands: Antioxidant-rich foods and high-dose antioxidant pills are not interchangeable. Randomized trials do not show a general longevity benefit from antioxidant supplements, and beta-carotene, vitamin A, and vitamin E have caused harm in specific doses and populations.
A small Alzheimer feasibility trial found administration was possible but did not establish cognitive rejuvenation, disease modification, or benefit in healthy adults.
Where the evidence lands: Young-plasma enthusiasm comes from complex animal experiments. The small human Alzheimer trial established feasibility, not cognitive benefit or age reversal in healthy people.
Both target core aging pathways and both are studied for healthspan, but they are prescription-only, not sold here, and the human data carry real caveats.
Where the evidence lands: Rapamycin and metformin hit real aging pathways and show early human signals, but both are prescription-only with meaningful risks, including metformin blunting exercise gains, and neither is a proven longevity treatment.
Harvard's ClockBase platform analyzes thousands of datasets across 40+ aging clocks to uncover aging interventions and disease links, but stresses that no single biological age number is…
Where the evidence lands: ClockBase reveals that while aging clocks like Horvath and DunedinPACE can uncover promising longevity interventions and disease links, the clocks often disagree, so trends matter more than any single biological age number.
43 distinct peer-reviewed papers, published 1994–2026, across 33 journals. Each links to its PubMed record; where Magellan has published a full study write-up, that is linked too.
Prefer the interactive version? Open the article feed in the Magellan app →